{"id":57712,"date":"2026-02-24T15:49:53","date_gmt":"2026-02-24T07:49:53","guid":{"rendered":"https:\/\/flcube.com\/?p=57712"},"modified":"2026-02-24T15:49:54","modified_gmt":"2026-02-24T07:49:54","slug":"pfizer-partners-with-sciwind-biosciences-for-ecnoglutide-china-rights-495m-deal-marks-metabolic-market-entry","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57712","title":{"rendered":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry"},"content":{"rendered":"\n<p><strong>Pfizer Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE:\u202fPFE<\/a>)<\/strong> has entered into an exclusive commercialization agreement with <strong>Sciwind Biosciences Co., Ltd.<\/strong> for <strong>ecnoglutide<\/strong>, a <strong>next\u2011generation biased GLP\u20111 receptor agonist<\/strong> approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures <strong>exclusive commercialization rights in Mainland China<\/strong>, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the <strong>Marketing Authorization Holder (MAH)<\/strong> status and will continue to handle R&amp;D, registration, manufacturing, and supply.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Sciwind Biosciences Co., Ltd. (China)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Pfizer Inc. (NYSE:\u202fPFE)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ecnoglutide (biased GLP\u20111 receptor agonist)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive commercialization)<\/td><\/tr><tr><td><strong>MAH Status<\/strong><\/td><td>Retained by Sciwind Bio<\/td><\/tr><tr><td><strong>Sciwind Responsibilities<\/strong><\/td><td>R&amp;D, registration, manufacturing, supply<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to <strong>USD\u202f495\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Upfront + development, regulatory, and sales\u2011based milestones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-ecnoglutide\">Product Profile \u2013 Ecnoglutide<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Next\u2011generation <strong>biased GLP\u20111 receptor agonist<\/strong> with unique signaling selectivity<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Type\u202f2 diabetes (approved); long\u2011term weight management (MAA accepted)<\/li>\n\n\n\n<li><strong>NMPA Approval:<\/strong> January\u202f2026 for T2D in adults<\/li>\n\n\n\n<li><strong>Pending Approval:<\/strong> Weight management indication (MAA under NMPA review)<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> Designed for <strong>more precise treatment<\/strong> in diabetes and obesity populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-chinese-population-data\">Clinical Evidence \u2013 Chinese Population Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Ecnoglutide Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Placebo\u2011Adjusted Weight Reduction<\/strong><\/td><td><strong>15.1%<\/strong> mean body weight loss<\/td><td>Superior efficacy vs. standard GLP\u20111s<\/td><\/tr><tr><td><strong>Clinically Meaningful Weight Loss<\/strong><\/td><td><strong>92.8%<\/strong> of patients achieved threshold<\/td><td>High responder rate<\/td><\/tr><tr><td><strong>Glycemic Control (HbA1c\u202f&lt;\u202f7.0%)<\/strong><\/td><td><strong>&gt;\u202f80%<\/strong> of patients reached target<\/td><td>Excellent diabetes management<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable and manageable<\/td><td>Supports long\u2011term use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-impact\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer\u2019s China Metabolic Entry:<\/strong> The deal marks Pfizer\u2019s <strong>first strategic step<\/strong> into the global metabolic disease market within China, leveraging Sciwind\u2019s local regulatory and manufacturing capabilities while deploying Pfizer\u2019s commercial infrastructure.<\/li>\n\n\n\n<li><strong>GLP\u20111 Market Dynamics:<\/strong> With the explosive growth of GLP\u20111 agonists for diabetes and obesity, Pfizer gains immediate access to an <strong>NMPA\u2011approved asset<\/strong> with demonstrated superior weight\u2011loss efficacy in Chinese patients.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> China\u2019s metabolic disease market is projected to exceed <strong>$50\u202fbillion<\/strong> by 2030, driven by rising obesity and diabetes prevalence. Ecnoglutide\u2019s <strong>15.1% weight reduction<\/strong> positions it competitively against existing GLP\u20111 therapies.<\/li>\n\n\n\n<li><strong>Risk Sharing:<\/strong> The <strong>upfront\u2011plus\u2011milestone structure<\/strong> (up to $495M) aligns incentives while minimizing Pfizer\u2019s upfront capital exposure. Sciwind retains manufacturing control, ensuring supply chain continuity.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory timelines, commercial expectations, and milestone payments for the Pfizer\u2011Sciwind partnership. Actual results may differ due to risks including NMPA approval for the weight indication, market competition from established GLP\u20111 players, and pricing pressures in China\u2019s healthcare system.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[863,309,822],"class_list":["post-57712","post","type-post","status-publish","format-standard","hentry","category-company","tag-nyse-pfe","tag-pfizer","tag-sciwind-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&amp;D, registration, manufacturing, and supply.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57712\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&amp;D, registration, manufacturing, and supply.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57712\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T07:49:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T07:49:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry\",\"datePublished\":\"2026-02-24T07:49:53+00:00\",\"dateModified\":\"2026-02-24T07:49:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NYSE: PFE\",\"Pfizer\",\"Sciwind Biosciences\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57712#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57712\",\"name\":\"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-24T07:49:53+00:00\",\"dateModified\":\"2026-02-24T07:49:54+00:00\",\"description\":\"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&D, registration, manufacturing, and supply.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57712\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57712#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&D, registration, manufacturing, and supply.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57712","og_locale":"en_US","og_type":"article","og_title":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry","og_description":"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&D, registration, manufacturing, and supply.","og_url":"https:\/\/flcube.com\/?p=57712","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T07:49:53+00:00","article_modified_time":"2026-02-24T07:49:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57712#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57712"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry","datePublished":"2026-02-24T07:49:53+00:00","dateModified":"2026-02-24T07:49:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57712"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NYSE: PFE","Pfizer","Sciwind Biosciences"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57712#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57712","url":"https:\/\/flcube.com\/?p=57712","name":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-24T07:49:53+00:00","dateModified":"2026-02-24T07:49:54+00:00","description":"Pfizer Inc. (NYSE:\u202fPFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd. for ecnoglutide, a next\u2011generation biased GLP\u20111 receptor agonist approved for type\u202f2 diabetes in China. Under the deal, Pfizer secures exclusive commercialization rights in Mainland China, representing its first strategic move into the global metabolic field within the country. Sciwind Bio retains the Marketing Authorization Holder (MAH) status and will continue to handle R&D, registration, manufacturing, and supply.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57712#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57712"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57712#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights \u2013 $495M Deal Marks Metabolic Market Entry"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57712"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57712\/revisions"}],"predecessor-version":[{"id":57714,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57712\/revisions\/57714"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}